New research reveals full-length DUX4 protein can be produced in the muscles of people without FSHD, contradicting previous evidence placing it only in FSHD-affected tissue
Researchers supported in part by MDA have recently found evidence that production of the full-length version of a protein known as DUX4 — previously associated exclusively with facioscapulohumeral muscular dystrophy (FSHD) — also can occur in people who don't have the disease.
Researchers have identified a molecular switch that appears to lead to harmful gene activation in facioscapulohumeral MD
Researchers in Italy and Japan, supported in part by MDA, have identified what they believe is a molecular "switch" that may be inappropriately activating several genes in facioscapulohumeral muscular dystrophy (FSHD).
An 11½-minute interview with researcher Stephen Tapscott explores recent findings about the molecular basis of facioscapulohumeral MD
A protein called DUX4, inappropriately produced ("expressed") in skeletal muscle fibers, is emerging as a major factor in facioscapulohumeral muscular dystrophy (FSHD).
In FSHD-affected muscles, full-length DUX4 protein disrupts numerous biochemical pathways that normally would help muscle cells survive, mature and develop specialized roles.
New research explains probable ways in which DUX4 protein, if made at the wrong time and in the wrong place, leads to FSH dystrophy
Editor's note 2/2/12: This story was updated to reflect the availability of a podcast in which Stephen Tapscott is interviewed.
A little over a year ago, a team of researchers announced a crucial new finding that helped explain the molecular basis of facioscapulohumeral muscular dystrophy (FSHD).